This triple combination medication combines Sitagliptin 50mg, Glimepiride 1mg, and Metformin 1000mg to effectively manage type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor that enhances the incretin system to regulate blood glucose levels. Glimepiride stimulates insulin secretion from pancreatic beta cells, and Metformin improves insulin sensitivity while reducing hepatic glucose production. Together, they provide comprehensive glycemic control by targeting multiple pathways, making it suitable for patients inadequately controlled on monotherapy. This combination helps maintain optimal blood sugar levels, reduce HbA1c, and lowers the risk of diabetes-related complications when used alongside diet and lifestyle modifications.
